SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : The Financial Collapse of 2001 Unwinding

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: THE ANT who wrote (2816)2/27/2020 12:11:31 PM
From: elmatador  Read Replies (1) of 13801
 
remdesivir

An experimental treatment for the new coronavirus

The first patient enrolled was passenger repatriated to the US after being on the Diamond Princess cruise ship, which was quarantined off the coast of Japan and had an outbreak of the virus on board.


The trial aims to run at a number of sites around the world, in order to allow people in the largest geographic area possible to participate, says lead investigator Andre Kalil, a professor of internal medicine at the University of Nebraska Medical Center. The goal is to enroll around 400 people with COVID-19.


Only patients experiencing severe symptoms are eligible for the trial. “About 80 percent of people have mild disease. They will clear the infection on their own,” Kalil says. “The goal here is to help the ones that are in the most need, who acquired the virus and need to be in a hospital.”


The remdesivir trials are just a few of the dozens of ongoing clinical trials testing treatments for COVID-19, targeting tens of thousands of patients. The scale and speed are remarkable — even more so given that, only a few years ago, the public health community was reluctant to use experimental treatments during active outbreaks....


theverge.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext